Japanese film and technology company Fujifilm has applied its corporate branding to its recently acquired Daiichi Radioisotope Laboratories (DRL) subsidiary, with the division to be known as Fujifilm RI Pharma, effective April 1.
Fujifilm, the parent company of film and PACS company Fujifilm Medical, bought DRL in October 2006 from Japanese drug maker Daiichi Pharmaceutical. The division develops and manufactures radiopharmaceuticals used in nuclear medicine procedures in Japan.
DRL had revenues of 17.22 billion yen ($142.7 million) for its fiscal year ended March 31, 2006, with 420 employees. Its products include radiopharmaceuticals for brain, cardiac, and bone diagnostic procedures, as well as therapeutic agents for thyroid disease.
In announcing the name change, Fuji said the new identity indicates the division's status as a member of the Fuji group of companies. Fuji said that Fujifilm RI Pharma will play an important role in the company's expansion in the medical business, which Fuji regards as one of its most important fields.
By AuntMinnie.com staff writers
January 17, 2007
Related Reading
Fuji acquires cardiac PACS firm ProSolv, January 11, 2007
Amerinet awards two contracts to Fujifilm, January 10, 2007
Fuji wins Premier CR contract, December 15, 2006
Fujifilm Australia wins public healthcare contract, December 8, 2006
Fuji touts CR mammo, moves into flat-panel DR with RSNA launches, November 29, 2006
Copyright © 2007 AuntMinnie.com
